Eversept Partners LP Invests $5.43 Million in Assembly Biosciences, Inc. $ASMB

Eversept Partners LP bought a new position in shares of Assembly Biosciences, Inc. (NASDAQ:ASMB) during the fourth quarter, Holdings Channel.com reports. The fund bought 159,676 shares of the biopharmaceutical company’s stock, valued at approximately $5,431,000.

A number of other institutional investors and hedge funds have also bought and sold shares of the stock. Farallon Capital Management LLC purchased a new stake in Assembly Biosciences in the 3rd quarter valued at $31,426,000. RA Capital Management L.P. purchased a new stake in Assembly Biosciences in the 3rd quarter valued at $26,122,000. Commodore Capital LP purchased a new stake in Assembly Biosciences in the 3rd quarter valued at $25,600,000. Paradigm Biocapital Advisors LP purchased a new stake in Assembly Biosciences in the 4th quarter valued at $22,625,000. Finally, Vanguard Group Inc. raised its position in Assembly Biosciences by 97.8% in the 3rd quarter. Vanguard Group Inc. now owns 502,112 shares of the biopharmaceutical company’s stock valued at $12,854,000 after buying an additional 248,287 shares during the last quarter. 19.92% of the stock is owned by hedge funds and other institutional investors.

Assembly Biosciences Price Performance

Shares of Assembly Biosciences stock opened at $24.15 on Thursday. Assembly Biosciences, Inc. has a 1 year low of $16.50 and a 1 year high of $39.71. The firm has a market cap of $383.74 million, a PE ratio of -219.53 and a beta of 1.07. The stock has a fifty day moving average price of $27.32 and a 200-day moving average price of $29.15.

Assembly Biosciences (NASDAQ:ASMB) last announced its earnings results on Thursday, May 7th. The biopharmaceutical company reported ($0.54) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.65) by $0.11. Assembly Biosciences had a negative return on equity of 4.21% and a negative net margin of 8.98%.The firm had revenue of $8.21 million during the quarter, compared to analyst estimates of $9.27 million. As a group, equities analysts anticipate that Assembly Biosciences, Inc. will post 1.9 EPS for the current fiscal year.

Wall Street Analyst Weigh In

A number of equities research analysts recently commented on the company. Wall Street Zen lowered Assembly Biosciences from a “strong-buy” rating to a “hold” rating in a research report on Saturday, May 16th. HC Wainwright reissued a “buy” rating and issued a $50.00 price target on shares of Assembly Biosciences in a research report on Monday, May 4th. Guggenheim reissued a “buy” rating and issued a $43.00 price target on shares of Assembly Biosciences in a research report on Thursday, May 28th. Mizuho set a $45.00 target price on Assembly Biosciences and gave the company an “outperform” rating in a research report on Monday. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Assembly Biosciences in a research report on Monday, April 20th. Five investment analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat.com, Assembly Biosciences currently has an average rating of “Moderate Buy” and an average price target of $44.00.

About Assembly Biosciences

Assembly Biosciences, Inc (NASDAQ: ASMB) is a clinical-stage biotechnology company dedicated to the discovery, development and commercialization of novel therapies for hepatitis B virus (HBV) and hepatitis D virus (HDV) infections. The company’s core expertise lies in small-molecule modulation of viral proteins and host-targeted pathways to achieve sustained viral suppression and potential functional cure. Assembly’s research model integrates medicinal chemistry, structural biology and translational virology to advance its pipeline from early discovery through clinical development.

The company’s lead programs include core protein allosteric modulators (CpAMs) designed to disrupt the HBV lifecycle by interfering with capsid assembly and viral DNA replication, as well as prenylation inhibitors targeting the HDV lifecycle.